Cargando…

CpG Adjuvant in Allergen-Specific Immunotherapy: Finding the Sweet Spot for the Induction of Immune Tolerance

Prevalence and incidence of IgE-mediated allergic diseases have increased over the past years in developed and developing countries. Allergen-specific immunotherapy (AIT) is currently the only curative treatment available for allergic diseases that has long-term efficacy. Although AIT has been prove...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montamat, Guillem, Leonard, Cathy, Poli, Aurélie, Klimek, Ludger, Ollert, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940844/ https://www.ncbi.nlm.nih.gov/pubmed/33708195 http://dx.doi.org/10.3389/fimmu.2021.590054

Ejemplares similares

Comprehensive mapping of immune tolerance yields a regulatory TNF receptor 2 signature in a murine model of successful Fel d 1‐specific immunotherapy using high‐dose CpG adjuvant
por: Leonard, Cathy, et al.
Publicado: (2021)

Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated micropores
por: Hessenberger, Michael, et al.
Publicado: (2013)

CpG oligodeoxynucleotides as mucosal adjuvants
por: Iho, Sumiko, et al.
Publicado: (2015)

Digital health for allergen immunotherapy
por: Dramburg, Stephanie, et al.
Publicado: (2022)

CpG Oligonucleotides as Cancer Vaccine Adjuvants
por: Shirota, Hidekazu, et al.
Publicado: (2015)

Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG
por: van den Boorn, Jasper G., et al.
Publicado: (2010)

CpG-Based Nanovaccines for Cancer Immunotherapy
por: Chen, Wenqiang, et al.
Publicado: (2021)

Clinical endpoints in allergen immunotherapy: State of the art 2022
por: Gerth van Wijk, Roy, et al.
Publicado: (2023)

CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein
por: Li, Yibo, et al.
Publicado: (2023)

Is The Allergen Really Needed in Allergy Immunotherapy?
por: Kündig, Thomas M., et al.
Publicado: (2014)

A comparison of nanoparticullate CpG immunotherapy with and without allergens in spontaneously equine asthma‐affected horses, an animal model
por: Klier, John, et al.
Publicado: (2017)

Antibody targeted CpG for the immunotherapy of solid tumors
por: Epstein, Alan L, et al.
Publicado: (2015)

The revival of CpG oligonucleotide-based cancer immunotherapies
por: Adamus, Tomasz, et al.
Publicado: (2018)

Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy
por: De Souza Rebouças, Juliana, et al.
Publicado: (2012)

Allergen-Specific Immunotherapy With Liposome Containing CpG-ODN in Murine Model of Asthma Relies on MyD88 Signaling in Dendritic Cells
por: Alberca-Custodio, Ricardo Wesley, et al.
Publicado: (2020)

Preservation of methylated CpG dinucleotides in human CpG islands
por: Panchin, Alexander Y., et al.
Publicado: (2016)

CpG 684: an effective adjuvant for the inactivated COVID-19 vaccine in mice
por: Liu, Jiandong, et al.
Publicado: (2023)

Suppressive CpG
por: Van Epps, Heather L.
Publicado: (2005)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Factors to preserve CpG-rich sequences in methylated CpG islands
por: Miyahara, Hiroki, et al.
Publicado: (2015)

Real‐world evidence for the long‐term effect of allergen immunotherapy: Current status on database‐derived European studies
por: Vogelberg, Christian, et al.
Publicado: (2022)

Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial
por: Ursu, Renata, et al.
Publicado: (2015)

Evidence vs. efficacy in allergen-specific immunotherapy: Considerations using the example of tradable products in Germany
por: Brehler, Randolf, et al.
Publicado: (2016)

COVID‐19 pandemic and allergen immunotherapy—an EAACI survey
por: Pfaar, Oliver, et al.
Publicado: (2021)

CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity
por: Chu, Rose S., et al.
Publicado: (1997)

Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
por: Gungor, Bilgi, et al.
Publicado: (2014)

Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant
por: Ito, Sayami, et al.
Publicado: (2020)

Overcoming Aging-Associated Poor Influenza Vaccine Responses with CpG 1018 Adjuvant
por: Kang, Xinliang, et al.
Publicado: (2022)

In Vivo Control of CpG and Non-CpG DNA Methylation by DNA Methyltransferases
por: Arand, Julia, et al.
Publicado: (2012)

CpG and Non-CpG Methylation in Epigenetic Gene Regulation and Brain Function
por: Jang, Hyun Sik, et al.
Publicado: (2017)

Allergen-specific immunotherapy of Hymenoptera venom allergy – also a matter of diagnosis
por: Schiener, Maximilian, et al.
Publicado: (2017)

Salt: the sweet spot?( )
por: Rosengren, Annika
Publicado: (2022)

The TLR9 ligand CpG ODN 2006 is a poor adjuvant for the induction of de novo CD8(+) T-cell responses in vitro
por: Papagno, Laura, et al.
Publicado: (2020)

Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy
por: Bartish, Margarita, et al.
Publicado: (2020)

Prediction of CpG-island function: CpG clustering vs. sliding-window methods
por: Hackenberg, Michael, et al.
Publicado: (2010)

CpG Methylation Altered the Stability and Structure of the i-Motifs Located in the CpG Islands
por: Oshikawa, Daiki, et al.
Publicado: (2022)

CpG ODN and ISCOMATRIX Adjuvant: A Synergistic Adjuvant Combination Inducing Strong T-Cell IFN-γ Responses
por: McCluskie, Michael J., et al.
Publicado: (2013)

Nanoparticulate CpG Immunotherapy in RAO‐Affected Horses: Phase I and IIa Study
por: Klier, J., et al.
Publicado: (2015)

Influenza T-cell Epitope-Loaded Virosomes Adjuvanted with CpG as a Potential Influenza Vaccine
por: Soema, Peter C., et al.
Publicado: (2014)

1057. CpG-adjuvanted Hepatitis B vaccination improves seroprotection rates in Veterans with HIV
por: Deming, Meagan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g3gnlqsagqak0h4tgc0knuu74f